

# Accepted Manuscript

Safety Analysis of 4 Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma

Susan O'Brien, Peter Hillmen, Steven Coutre, Paul M. Barr, Graeme Fraser, Alessandra Tedeschi, Jan A. Burger, Marie-Sarah Dilhuydy, Georg Hess, Carol Moreno, Paula Cramer, Emily Liu, Stephen Chang, Jessica Vermeulen, Lori Styles, Angela Howes, Danelle F. James, Kalpesh Patel, Thorsten Graef, Rudolph Valentino

PII: S2152-2650(18)30265-9

DOI: [10.1016/j.clml.2018.06.016](https://doi.org/10.1016/j.clml.2018.06.016)

Reference: CLML 1143

To appear in: *Clinical Lymphoma, Myeloma and Leukemia*


Received Date: 14 March 2018

Revised Date: 16 June 2018

Accepted Date: 19 June 2018

Please cite this article as: O'Brien S, Hillmen P, Coutre S, Barr PM, Fraser G, Tedeschi A, Burger JA, Dilhuydy M-S, Hess G, Moreno C, Cramer P, Liu E, Chang S, Vermeulen J, Styles L, Howes A, James DF, Patel K, Graef T, Valentino R, Safety Analysis of 4 Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma, *Clinical Lymphoma, Myeloma and Leukemia* (2018), doi: 10.1016/j.clml.2018.06.016.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1 **Safety Analysis of 4 Randomized Controlled Studies of Ibrutinib in Patients With**  
2 **Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell**  
3 **Lymphoma**

4 Susan O'Brien,<sup>a</sup> Peter Hillmen,<sup>b</sup> Steven Coutre,<sup>c</sup> Paul M. Barr,<sup>d</sup> Graeme Fraser,<sup>e</sup>  
5 Alessandra Tedeschi,<sup>f</sup> Jan A. Burger,<sup>g</sup> Marie-Sarah Dilhuydy,<sup>h</sup> Georg Hess,<sup>i</sup> Carol  
6 Moreno,<sup>j</sup> Paula Cramer,<sup>k</sup> Emily Liu,<sup>l</sup> Stephen Chang,<sup>l</sup> Jessica Vermeulen,<sup>m</sup> Lori Styles,<sup>l</sup>  
7 Angela Howes,<sup>n</sup> Danelle F. James,<sup>l</sup> Kalpesh Patel,<sup>o</sup> Thorsten Graef,<sup>l</sup> Rudolph Valentino<sup>l</sup>

8 <sup>a</sup>University of California Irvine, Chao Family Comprehensive Cancer Center, Orange,  
9 CA, USA

10 <sup>b</sup>The Leeds Teaching Hospitals, St. James University Hospital, Leeds, UK

11 <sup>c</sup>Stanford University School of Medicine, Stanford, CA, USA

12 <sup>d</sup>Wilmot Cancer Institute, University of Rochester Cancer Center, Rochester, NY, USA

13 <sup>e</sup>Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, CA, USA

14 <sup>f</sup>ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

15 <sup>g</sup>University of Texas MD Anderson Cancer Center, Houston, TX, USA

16 <sup>h</sup>CHU Hopitaux de Bordeaux, Pessac, France

17 <sup>i</sup>Universitätsmedizin Mainz, Mainz, Germany

18 <sup>j</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

19 <sup>k</sup>University of Cologne, German CLL Study Group, Cologne, Germany

20 <sup>l</sup>Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA

21 <sup>m</sup>Janssen Research & Development, Leiden, The Netherlands

22 <sup>n</sup>Janssen Research & Development, Raritan, NJ, USA

23 <sup>o</sup>Janssen Pharmaceuticals, Inc., Titusville, NJ, USA

24

25 **Address for correspondence:** Susan O'Brien, MD, Associate Director for Clinical  
26 Sciences, Chao Family Comprehensive Cancer Center, Medical Director, Sue and  
27 Ralph Stern Center for Clinical Trials and Research, Professor of Medicine, Division of  
28 Hematology/Oncology, University of California Irvine, Orange, CA 92868  
29 E-mail contact: [obrien@uci.edu](mailto:obrien@uci.edu)

30

31 **Coauthors:**

32 Peter Hillmen MB ChB, PhD  
33 University of Leeds, St. James's University Hospital  
34 Level 6, Wellcome Trust Brenner Building  
35 E Leeds Link Interchange  
36 Leeds LS9, United Kingdom  
37 Email: [peter.hillmen@nhs.net](mailto:peter.hillmen@nhs.net)  
38 Phone: 0113 343 8525

39

40

41 Steven Coutre MD  
42 Stanford Cancer Center  
43 875 Blake Wilbur Dr  
44 Palo Alto, CA 94304

Download English Version:

<https://daneshyari.com/en/article/10211915>

Download Persian Version:

<https://daneshyari.com/article/10211915>

[Daneshyari.com](https://daneshyari.com)